Allogeneic Bone Marrow Transplant From HLA Identical Related Donors for Patients With High Risk Hemoglobinopathies: Hemoglobin SS, Hemoglobin SC, Hemoglobin SB0/+ Thalassemia, or Homozygous B0/+ Thalassemia or Severe Variants of B0/+ Thalassemia

Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies

Sponsors

Lead sponsor: Baylor College of Medicine

Collaborator: The Methodist Hospital System
Center for Cell and Gene Therapy, Baylor College of Medicine

Source Baylor College of Medicine
Brief Summary

The major goal of this study is to determine the risks and benefits of bone marrow transplants in patients with severe thalassemia or sickle cell disease. Participation in this project will be for two years.

Detailed Description

To do the bone marrow transplant, we must first kill the cells in the bone marrow that make the abnormal red blood cells that are found in patients with severe thalassemia or sickle cell disease.

We will do this by using three drugs: busulfan, cyclophosphamide, and CAMPATH-1H. CAMPATH-IH is an investigational drug. CAMPATH-1H is used to prevent participants from rejecting or refusing to let the donor blood cells grow in the body. After the drug treatment, participants will be given bone marrow from a brother or sister who has healthy bone marrow that matches.

Overall Status Terminated
Start Date August 2000
Completion Date November 21, 2003
Primary Completion Date November 21, 2003
Phase Phase 2
Study Type Interventional
Enrollment 15
Condition
Intervention

Intervention type: Drug

Intervention name: Campath -1H

Intervention type: Drug

Intervention name: Dilantin

Intervention type: Drug

Intervention name: Busulfan

Intervention type: Drug

Intervention name: Cyclophosphamide

Eligibility

Criteria:

Inclusion:

- Patients with homozygous B0/+ thalassemia or severe variants of B0/+ thalassemia with an HLA genotypically identical donor.

- Patients with an HLA genotype identical donor and hemoglobin SS, hemoglobin SC, or hemoglobin Sb 0/+ and at least one of the following:

Previous central nervous system vaso-occlusive episode with or without residual neurologic findings; Frequent painful vaso-occlusive episodes which significantly interfere with normal life activities and which necessitate chronic transfusion therapy; Recurrent SCD chest syndrome events which necessitate chronic transfusion therapy.

- Severe anemia which prevents acceptable quality of life and necessitates chronic transfusion therapy.

- The patient must have an HLA genotype identical donor.

- Between the ages of birth and 65 years.

- Women of childbearing potential must have a negative pregnancy test.

Exclusion:

- Biopsy proven chronic active hepatitis or fibrosis with portal bridging.

- SCD chronic lung disease >/= stage 3.

- Severe renal dysfunction defined as creatinine clearance <40 ml/min/1.73 M2

- Severe cardiac dysfunction defined as shortening fraction <25%.

- HIV infection.

- Severe but unspecified chronic toxicity serious enough to detrimentally affect the patient's capacity to tolerate bone marrow transplant (BMT).

- Inadequate intellectual capacity to understand the nature and risk inherent in the BMT process and give informed consent (in the case of minors, this criteria must be fulfilled by the legal guardian).

- Pregnant, lactating or unwilling to use appropriate birth control.

Gender: All

Minimum age: N/A

Maximum age: 64 Years

Healthy volunteers: No

Overall Official
Last Name Role Affiliation
Malcolm K. Brenner, MD Study Chair Baylor College of Medicine
Location
facility
Texas Children's Hospital | Houston, Texas, 77030, United States
The Methodist Hospital | Houston, Texas, 77030, United States
Location Countries

United States

Verification Date

January 2020

Responsible Party

Responsible party type: Principal Investigator

Investigator affiliation: Baylor College of Medicine

Investigator full name: Robert Krance

Investigator title: Professor

Condition Browse
Study Design Info

Allocation: Non-Randomized

Intervention model: Single Group Assignment

Primary purpose: Treatment

Masking: None (Open Label)

Source: ClinicalTrials.gov